Sept 15 (Reuters) - ADOCIA SA ADOC.PA :
* ADOCIA ANNOUNCES POSITIVE TOPLINE RESULTS OF PHASE 1B
STUDY FOR
M1PRAM IN PEOPLE WITH TYPE 1 DIABETES
* PRIMARY ENDPOINT MET: REDUCTION OF 69% OF POST-MEAL
GLYCEMIC
EXCURSIONS (DELTA AUC-PG) OVER FOUR HOURS VERSUS.
NOVOLOG(®)(P=0.03)
* BOTH TREATMENTS WERE WELL TOLERATED, AND NO SERIOUS
ADVERSE
EVENTS WERE REPORTED DURING 24 DAYS OF TREATMENT
Source text for Eikon: ID:nBw9t9blla
Further company coverage: ADOC.PA
(Gdansk Newsroom)
((Gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))